← Back to Search

Mucolytic Agent

N-acetyl cysteine then Placebo for Pulmonary fibrosis

Phase 1 & 2
Waitlist Available
Led By Mark Steele, MD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 10, and week 18

Summary

This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research.

Eligible Conditions
  • Pulmonary fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 10, and week 18
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 10, and week 18 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in Pulmonary function - DLCO
Changes in Pulmonary function - FVC

Trial Design

2Treatment groups
Experimental Treatment
Group I: Placebo then N-acetyl cysteineExperimental Treatment1 Intervention
This arm will receive placebo followed by NAC
Group II: N-acetyl cysteine then placeboExperimental Treatment1 Intervention
This arm will receive NAC followed by placebo

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,806 Previous Clinical Trials
2,822,877 Total Patients Enrolled
Mark Steele, MDPrincipal InvestigatorUniversity of Colorado, Denver
~0 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top